Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P10721 (
c-kit
)
6,575
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Stem cell factor (SCF) binds the receptor tyrosine kinase
c-Kit
and is critical for normal hematopoiesis. Substitution of valine for aspartic acid 816 (D816V) constitutively actives human
c-Kit
, and this mutation is found in patients with mastocytosis, leukemia, and germ cell tumors. Immortalized murine progenitor cells (MIHCs) transduced with wild-type
c-Kit
proliferate in response to SCF, whereas cells expressing D816V
c-Kit
(
MIHC
-D816V) are factor-independent and tumorigenic. However, the mechanisms mediating transformation by D816V
c-Kit
are unknown. The objective of this study was to identify signaling components that contribute to D816V
c-Kit
-mediated transformation. SCF stimulates association of p85PI3K with phosphorylated tyrosine 721 of wild-type
c-Kit
. Phosphatidylinositol 3 kinase (PI3K) subsequently contributes to the activation of Akt and Jnks. In contrast, these studies demonstrated that the D816V
c-Kit
mutant was constitutively associated with phosphorylated p85PI3K, and, downstream of PI3K, Jnk 1 and Jnk 2 were activated but Akt was not. Interestingly, Erks 1 and 2 were not constitutively activated by D816V
c-Kit
. Thus, D816V
c-Kit
maintains the activity of PI3K but not of all signaling pathways activated by wild-type
c-Kit
. Further, all pathways downstream of PI3K are not constitutively active in
MIHC
-D816V cells. Studies with a PI3K inhibitor and D816V/Y721F
c-Kit
, a mutant incapable of recruiting PI3K, indicate that constitutive activation of PI3K through direct recruitment by D816V
c-Kit
plays a role in factor-independent growth of
MIHC
and is critical for tumorigenicity.
...
PMID:Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. 1152 Jul 84